Skip to main navigation Skip to search Skip to main content

Quality of Life Results of Addition of Androgen Deprivation Therapy and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiation Therapy: NRG Oncology/RTOG 0534 SPPORT

  • Deborah W Bruner
  • , Theodore G Karrison
  • , Alan Pollack
  • , Jeff M Michalski
  • , Alexander G Balogh
  • , George B Rodrigues
  • , Eric M Horwitz
  • , Sergio L Faria
  • , Andrew S Camarata
  • , R Jeffrey Lee
  • , Himanshu R Lukka
  • , Michael Zelefsky
  • , Wendy Seiferheld
  • , Howard Sandler
  • , Benjamin Movsas
  • Emory University Hospital/Winship Cancer Institute
  • University of Chicago
  • University of Miami Miller School of Medicine-Sylvester Cancer Center
  • Washington University School of Medicine
  • Tom Baker Cancer Centre
  • London Regional Cancer Program
  • Fox Chase Cancer Center and the Lewis Katz School of Medicine at Temple University
  • McGill University Health Centre
  • Uniformed Services University of the Health Sciences
  • Intermountain Medical Center
  • Juravinski Cancer Center at Hamilton Health Sciences
  • New York University Langone Medical Center
  • American College of Radiology
  • Oregon Health and Science University
  • Henry Ford Cancer Institute/Henry Ford Health System

Research output: Contribution to journal › Article › peer-review

Abstract

PURPOSE: This is the quality of life (QOL) analysis of the SPPORT trial of men with a detectable prostate specific antigen after prostatectomy for prostate cancer. Primary analysis established a benefit of adding pelvic lymph node radiation therapy (PLNRT) and short-term androgen deprivation therapy (STADT) to salvage prostate bed radiation therapy (PBRT) for biochemical progression-free survival.

METHODS AND MATERIALS: Subjects were randomized to Arm 1, PBRT, Arm 2, 4-6 months of STADT + PBRT, or Arm 3, PLNRT + STADT + PBRT. QOL was assessed at baseline, 6 weeks after the start of radiation therapy (RT), 1 and 5 years after the end of RT, including Expanded Prostate Cancer Index Composite, Hopkins Symptom Checklist, EuroQol, and quality-adjusted life years (QALYs). Statistical and clinical significance were calculated. Differences among arms were assessed using pairwise t-tests, Fisher's exact test, and mixed effects regression modeling, controlling for multiplicity.

RESULTS: Six hundred forty four patients consented to QOL; 81% white and 54% <65 years. Expanded Prostate Cancer Index Composite, bowel and urinary scores decreased at 6 weeks then increased by years 1 and 5, although not to baseline. For sexual and hormonal domains, there were statistically significant differences between arms at 6 weeks and 1 year with STADT exhibiting poorer QOL scores, but no difference at 5 years. For Hopkins Symptom Checklist, statistically significant differences at 6 weeks were not clinically significant. Comparisons of QALYs for overall survival showed no statistical significance. However, freedom from progression QALY means were 5.5, 6.2, and 6.6 years for Arms 1, 2, and 3, respectively, with Arms 3 and 2 indicating statistically significant improvement over Arm 1.

CONCLUSIONS: Although QOL generally declined the most among all arms at 6 weeks post-RT initiation, and remained lower than baseline at 5 years, there were no clinically significant differences in QOL among arms at 1 and 5 years. QALYs for freedom from progression favored STADT + PLNRT + PBRT for salvage treatment of prostate cancer.

Original languageEnglish
JournalInternational Journal of Radiation Oncology Biology Physics
Early online dateJul 14 2026
DOIs
StateE-pub ahead of print - Jul 14 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Quality of Life Results of Addition of Androgen Deprivation Therapy and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiation Therapy: NRG Oncology/RTOG 0534 SPPORT'. Together they form a unique fingerprint.

Cite this